177748-17-3

Basic information

• Product Name: (E)-1-(4-HYDROXYPHENYL)-1-[4-(TRIMETHYLACETOXY)PHENYL]-2-PHENYLBUT-1-ENE
• Synonyms: (E)-1-(4-HYDROXYPHENYL)-1-[4-(TRIMETHYLACETOXY)PHENYL]-2-PHENYLBUT-1-ENE;(E)-2,2-DiMethyl-propanoic Acid 4-[1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenyl Ester;(E)-4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl pivalate;(E)-4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenyl pivalate(WXC07047)
• CAS NO: 177748-17-3
• Molecular Formula: C27H28O3
• Molecular Weight: 400.51
• Product Categories: Drug Analogues;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 177748-17-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 171-173°C
• Boiling Point: 509.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.109±0.06 g/cm3(Predicted)
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• PKA: 10.25±0.15(Predicted)
• CAS DataBase Reference: (E)-1-(4-HYDROXYPHENYL)-1-[4-(TRIMETHYLACETOXY)PHENYL]-2-PHENYLBUT-1-ENE(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-1-(4-HYDROXYPHENYL)-1-[4-(TRIMETHYLACETOXY)PHENYL]-2-PHENYLBUT-1-ENE(177748-17-3)
• EPA Substance Registry System: (E)-1-(4-HYDROXYPHENYL)-1-[4-(TRIMETHYLACETOXY)PHENYL]-2-PHENYLBUT-1-ENE(177748-17-3)

Safety Data

• Hazardous Substances Data: 177748-17-3(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 177748-17-3 differently. You can refer to the following data:
1. A analogue of tamoxifen with anti-estrogenic properties
2. A analogue of tamoxifen with anti-estrogenic properties.

Upstream product

• 3282-30-2 pivaloyl chloride 
• 93-55-0 1-phenyl-propan-1-one 
• 114031-67-3 [4-(4-hydroxybenzoyl)phenyl]-2,2-dimethyl propanoate 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 111983-36-9 [4-(tert-Butyldimethylsilanyloxy)phenyl]-(4-hydroxyphenyl)methanone 
• 112004-83-8 [4-[4-(2,2-dimethylpropanoyloxy)benzoyl]phenyl] 2,2-dimethylpropanoate 
• 93-54-9 1-Phenyl-1-propanol 
• 364635-60-9 1-(4-trimethylacetoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-ene 
• 7065-46-5 3,3-dimethylbutanoic acid chloride 

Downstream Products

• 1440533-08-3 (Z)-4-(1-(4-(2-amino-2-oxoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl Pivalate 
• 1440533-06-1 (E)-4-(1-(4-(2-amino-2-oxoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl Pivalate 
• 1308808-22-1 (Z)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-enyl)phenol 
• 1394929-55-5 (E)-4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-enyl)phenol 

Relevant articles and documents

Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer

Anticancer drug conjugates may benefit from simultaneous action at two targets potentially overcoming the drawbacks of current cancer treatment, such as insufficient efficacy, high toxicity, and development of resistance. Compared to a combination of two single-target drugs, they may offer an advantage of pharmacokinetic simplicity and fewer drug-drug interactions. Here, we report a series of compounds connecting tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. These hybrid ligands retain both ER antagonist activity and EGFR inhibition. The most potent analogues exhibited single-digit nanomolar activities at both targets. The amide-linked endoxifen-gefitinib drug conjugates 17b and 17c demonstrated the most favorable anti-cancer profile in cellular viability assays on MCF7, MDA-MB-231, MDA-MB-468, and BT-549 breast cancer cells. Most importantly, in TNBC cells 17b and 17c displayed nanomolar IC50-values (380 nM - 970 nM) and were superior in their anti-cancer activity compared to their control compounds and combinations thereof.

Rational design of ERα targeting hypoxia turn-on fluorescent probes with antiproliferative activity for breast cancer

The overexpression of estrogen receptor (ER) α is not only closely related to the development of ER+ breast cancer, but is also an important biomarker for clinical diagnosis and treatment. Herein, we report several ERα targeting hypoxia turn-on fluorescent probes with antitumor activity for breast cancer cells. Among them, probes 3 and 5 displayed good ERα targeting ability and favorable hypoxia turn-on response in MCF-7 cells. Moreover, the probes 3 and 5 exhibited good antiproliferative activity towards MCF-7 cells (IC50 = 8.5 μM, 10.3 μM) and a much lower cytotoxicity to normal cells compared with the positive control. It is expected that these novel fluorescent probes may provide useful tools for the theranostics of ER+ breast cancer.

A multi-gram-scale stereoselective synthesis of Z-endoxifen

Z-Endoxifen is widely regarded as the most active metabolite of tamoxifen, and has recently demonstrated a 26.3% clinical benefit in a phase I clinical trial to treat metastatic breast cancer after the failure of standard endocrine therapy. Future pharmac